MAIA Biotechnology, Inc Announces Formation of Scientific Advisory Board apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
More Evidence Once-Weekly Semaglutide Injection Helps People With Diabetes Lose Weight
Sold in a lower dose under the brand names Ozempic and Rybelsus to treat type 2 diabetes, semaglutide may also be safe and effective for chronic weight management, a new study suggests.
March 8, 2021
Semaglutide is sold as the injectable Ozempic, which is a GLP1 agonist that mimics the feel-full hormone, possibly aiding weight loss.
Everyday Health
A higher-dose version of an injected drug approved for type 2 diabetes may help many people with this condition who also have overweight or obesity lose at least 5 percent of their body weight a threshold that can help reduce the risk of many weight-related chronic health problems.
◆
A National Science Foundation (NSF) Office of Inspector General (OIG) audit of five Established Program to Stimulate Competitive Research (EPSCoR) awards to the University of Kansas Center for Research (KUCR) questioned $1,550,054 in direct and indirect costs. The largest amount, $625,532, stemmed from what auditors called “inappropriately retained indirect costs.” KUCR’s charges to NSF “exceeded costs paid to its subrecipients,” auditors said in the Jan. 7 report. Subrecipients, under a 2016 agreement, “billed KUCR for indirect costs on EPSCoR awards at rates that were 8 percentage points lower than their formal negotiated indirect cost rates. KUCR paid subrecipients at the lower rates, but it charged the EPSCoR awards for allowable indirect costs at the full, negotiated indirect cost rates and retained the remainder.” Auditors said NSF was not aware of this arrangement. “KUCR agreed to end the practice,” according to the report, but disagreed that its action
RA Session II, founder, president and CEO of Taysha (Taysha Gene Therapies)
Taysha Gene Therapies hit the ground running when it launched this spring, cruising through a $95 million series B straight to a $100 million IPO in September. With its lead program now approved for human trials in Canada, the company is sketching out plans for what it hopes will become its prime commercial manufacturing site.
Taysha leased a 187,000-square-foot commercial-scale manufacturing facility in Durham, North Carolina, planning to invest $75 million to kit out the facility for preclinical, clinical and commercial gene therapy production. It’s also due to receive up to $9.4 million in state and local incentives for the project, Taysha said in a release.